

# Sandra - Pellegrini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/400922/publications.pdf>

Version: 2024-02-01

93  
papers

10,253  
citations

43973

48  
h-index

49773

87  
g-index

104  
all docs

104  
docs citations

104  
times ranked

11347  
citing authors

#	ARTICLE	IF	CITATIONS
1	A partial form of inherited human USP18 deficiency underlies infection and inflammation. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	28
2	Integrative genetic and immune cell analysis of plasma proteins in healthy donors identifies novel associations involving primary immune deficiency genes. <i>Genome Medicine</i> , 2022, 14, 28.	3.6	8
3	Rhesus negative males have an enhanced IFN $\gamma$ -mediated immune response to influenza A virus. <i>Genes and Immunity</i> , 2022, 23, 93-98.	2.2	2
4	A loss-of-function <i>IFNAR1</i> allele in Polynesia underlies severe viral diseases in homozygotes. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	28
5	Early IFN $\gamma$ secretion determines variable downstream IL-12p70 responses upon TLR4 activation. <i>Cell Reports</i> , 2022, 39, 110989.	2.9	4
6	Immune Profiling Enables Stratification of Patients With Active Tuberculosis Disease or <i>Mycobacterium tuberculosis</i> Infection. <i>Clinical Infectious Diseases</i> , 2021, 73, e3398-e3408.	2.9	18
7	Herpes simplex encephalitis in a patient with a distinctive form of inherited <i>IFNAR1</i> deficiency. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	64
8	Genome-Wide Gene Expression Analysis of <i>Mtb</i> -Infected DC Highlights the Rapamycin-Driven Modulation of Regulatory Cytokines via the mTOR/GSK-3 $\beta$ Axis. <i>Frontiers in Immunology</i> , 2021, 12, 649475.	2.2	4
9	Altered Immune Phenotypes and HLA-DQB1 Gene Variation in Multiple Sclerosis Patients Failing Interferon $\gamma$ Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 628375.	2.2	0
10	An Old Cytokine Against a New Virus?. <i>Journal of Interferon and Cytokine Research</i> , 2020, 40, 425-428.	0.5	9
11	COPZ1 depletion in thyroid tumor cells triggers type I IFN response and immunogenic cell death. <i>Cancer Letters</i> , 2020, 476, 106-119.	3.2	7
12	Two common disease-associated TYK2 variants impact exon splicing and TYK2 dosage. <i>PLoS ONE</i> , 2020, 15, e0225289.	1.1	25
13	Human Ubiquitin-Specific Peptidase 18 Is Regulated by microRNAs via the 3' Untranslated Region, A Sequence Duplicated in Long Intergenic Non-coding RNA Genes Residing in chr22q11.21. <i>Frontiers in Genetics</i> , 2020, 11, 627007.	1.1	12
14	USP18 and ISG15 coordinately impact on SKP2 and cell cycle progression. <i>Scientific Reports</i> , 2019, 9, 4066.	1.6	30
15	Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors. <i>Nature Immunology</i> , 2018, 19, 302-314.	7.0	205
16	Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E488-E497.	3.3	181
17	Tuberculosis and impaired IL-23-dependent IFN- $\gamma$ immunity in humans homozygous for a common <i>TYK2</i> missense variant. <i>Science Immunology</i> , 2018, 3, .	5.6	148
18	Copy number variations and founder effect underlying complete IL-10R $\beta$ deficiency in Portuguese kindreds. <i>PLoS ONE</i> , 2018, 13, e0205826.	1.1	13

#	ARTICLE	IF	CITATIONS
19	Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines. <i>Genome Medicine</i> , 2018, 10, 59.	3.6	113
20	Type I interferon-enhanced IL-10 expression in human CD4 T cells is regulated by STAT3, STAT2, and BATF transcription factors. <i>Journal of Leukocyte Biology</i> , 2017, 101, 1181-1190.	1.5	8
21	STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling. <i>Nature Structural and Molecular Biology</i> , 2017, 24, 279-289.	3.6	140
22	ISG15 deficiency and increased viral resistance in humans but not mice. <i>Nature Communications</i> , 2016, 7, 11496.	5.8	156
23	Standardized Whole-Blood Transcriptional Profiling Enables the Deconvolution of Complex Induced Immune Responses. <i>Cell Reports</i> , 2016, 16, 2777-2791.	2.9	84
24	Mycolactone subverts immunity by selectively blocking the Sec61 translocon. <i>Journal of Experimental Medicine</i> , 2016, 213, 2885-2896.	4.2	101
25	Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome. <i>Journal of Experimental Medicine</i> , 2016, 213, 1163-1174.	4.2	224
26	The cyclin D1 carboxyl regulatory domain controls the division and differentiation of hematopoietic cells. <i>Biology Direct</i> , 2016, 11, 21.	1.9	7
27	ID: 140. <i>Cytokine</i> , 2015, 76, 92.	1.4	0
28	Assessment of mTOR-Dependent Translational Regulation of Interferon Stimulated Genes. <i>PLoS ONE</i> , 2015, 10, e0133482.	1.1	21
29	IFNA2: The prototypic human alpha interferon. <i>Gene</i> , 2015, 567, 132-137.	1.0	46
30	Receptor dimerization dynamics as a regulatory valve for plasticity of type I interferon signaling. <i>Journal of Cell Biology</i> , 2015, 209, 579-593.	2.3	103
31	The Milieu Intérieur study "An integrative approach for study of human immunological variance. <i>Clinical Immunology</i> , 2015, 157, 277-293.	1.4	71
32	Human intracellular ISG15 prevents interferon- $\beta$ over-amplification and auto-inflammation. <i>Nature</i> , 2015, 517, 89-93.	13.7	432
33	Functional Analysis via Standardized Whole-Blood Stimulation Systems Defines the Boundaries of a Healthy Immune Response to Complex Stimuli. <i>Immunity</i> , 2014, 40, 436-450.	6.6	192
34	Two Rare Disease-Associated Tyk2 Variants Are Catalytically Impaired but Signaling Competent. <i>Journal of Immunology</i> , 2013, 190, 2335-2344.	0.4	63
35	Type I interferon potentiates T cell receptor mediated induction of IL-10 producing CD4 <sup>+</sup> T cells. <i>European Journal of Immunology</i> , 2013, 43, 2730-2740.	1.6	25
36	USP18 establishes the transcriptional and anti-proliferative interferon $\beta$ differential. <i>Biochemical Journal</i> , 2012, 446, 509-516.	1.7	50

#	ARTICLE	IF	CITATIONS
37	Hepatitis B virus X protein inhibits extracellular IFN- $\lambda$ -mediated signal transduction by downregulation of type I IFN receptor. <i>International Journal of Molecular Medicine</i> , 2012, 29, 581-586.	1.8	39
38	Tyk2 and Stat3 Regulate Brown Adipose Tissue Differentiation and Obesity. <i>Cell Metabolism</i> , 2012, 16, 814-824.	7.2	81
39	USP18-Based Negative Feedback Control Is Induced by Type I and Type III Interferons and Specifically Inactivates Interferon $\lambda$ Response. <i>PLoS ONE</i> , 2011, 6, e22200.	1.1	225
40	Functional characterization of naturally occurring genetic variants in the human TLR1-2-6 gene family. <i>Human Mutation</i> , 2011, 32, 643-652.	1.1	28
41	Expression of IFN $\lambda$ 3R2 mutated in a dileucine internalization motif reinstates IFN $\lambda$ 3 signaling and apoptosis in human T lymphocytes. <i>Immunology Letters</i> , 2010, 134, 17-25.	1.1	12
42	Biochemical Monitoring of the Early Endocytic Traffic of the Type I Interferon Receptor. <i>Journal of Interferon and Cytokine Research</i> , 2010, 30, 89-98.	0.5	18
43	SS2-3 A cross-talk between the Stat3/SOCS3 and the IRS-1/PI3K/p70S6K pathways regulates antiproliferative activity of IFN $\lambda$ 2. <i>Cytokine</i> , 2010, 52, 13.	1.4	0
44	T Cell Receptor Signal Initiation Induced by Low-Grade Stimulation Requires the Cooperation of LAT in Human T Cells. <i>PLoS ONE</i> , 2010, 5, e15114.	1.1	16
45	Receptor Density Is Key to the Alpha2/Beta Interferon Differential Activities. <i>Molecular and Cellular Biology</i> , 2009, 29, 4778-4787.	1.1	91
46	Translational control as the basis of the differential antiproliferative potency of IFN $\lambda$ 2 and IFN $\lambda$ 1. <i>Cytokine</i> , 2009, 48, 120-121.	1.4	0
47	Biochemical monitoring of the early endocytic traffic of the type I interferon receptor. <i>Cytokine</i> , 2009, 48, 129-130.	1.4	0
48	Evolutionary Dynamics of Human Toll-Like Receptors and Their Different Contributions to Host Defense. <i>PLoS Genetics</i> , 2009, 5, e1000562.	1.5	341
49	Ligand-independent pathway that controls stability of interferon alpha receptor. <i>Biochemical and Biophysical Research Communications</i> , 2008, 367, 388-393.	1.0	45
50	Basal Ubiquitin-independent Internalization of Interferon $\lambda$ Receptor Is Prevented by Tyk2-mediated Masking of a Linear Endocytic Motif. <i>Journal of Biological Chemistry</i> , 2008, 283, 18566-18572.	1.6	46
51	Jakmip1 Is Expressed upon T Cell Differentiation and Has an Inhibitory Function in Cytotoxic T Lymphocytes. <i>Journal of Immunology</i> , 2008, 181, 5847-5856.	0.4	15
52	The Stat3-activating Tyk2 V678F Mutant Does Not Up-regulate Signaling through the Type I Interferon Receptor but Confers Ligand Hypersensitivity to a Homodimeric Receptor. <i>Journal of Biological Chemistry</i> , 2008, 283, 18522-18529.	1.6	11
53	NF- $\kappa$ B is required for STAT-4 expression during dendritic cell maturation. <i>Journal of Leukocyte Biology</i> , 2007, 81, 355-363.	1.5	33
54	Comparable potency of IFN $\lambda$ 2 and IFN $\lambda$ 1 on immediate JAK/STAT activation but differential down-regulation of IFNAR2. <i>Biochemical Journal</i> , 2007, 407, 141-151.	1.7	66

#	ARTICLE	IF	CITATIONS
55	Dendritic-cell maturation alters intracellular signaling networks, enabling differential effects of IFN- $\beta$ on antigen cross-presentation. <i>Blood</i> , 2007, 109, 1113-1122.	0.6	55
56	Genome-wide expression profiling of lymphoblastoid cell lines distinguishes different forms of autism and reveals shared pathways. <i>Human Molecular Genetics</i> , 2007, 16, 1682-1698.	1.4	290
57	TYK2 activity promotes ligand-induced IFNAR1 proteolysis. <i>Biochemical Journal</i> , 2006, 397, 31-38.	1.7	78
58	Differential responsiveness to IFN- $\alpha$ and IFN- $\beta$ of human mature DC through modulation of IFNAR expression. <i>Journal of Leukocyte Biology</i> , 2006, 79, 1286-1294.	1.5	67
59	A Dual Role of IFN- $\beta$ in the Balance between Proliferation and Death of Human CD4+ T Lymphocytes during Primary Response. <i>Journal of Immunology</i> , 2004, 173, 3740-3747.	0.4	51
60	Jamip1 (Marlin-1) Defines a Family of Proteins Interacting with Janus Kinases and Microtubules. <i>Journal of Biological Chemistry</i> , 2004, 279, 43168-43177.	1.6	39
61	The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. <i>EMBO Journal</i> , 2003, 22, 537-547.	3.5	183
62	A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 11594-11599.	3.3	120
63	Down-Modulation of Responses to Type I IFN Upon T Cell Activation. <i>Journal of Immunology</i> , 2003, 170, 749-756.	0.4	67
64	Selective Expression of Type I IFN Genes in Human Dendritic Cells Infected with <i>Mycobacterium tuberculosis</i> . <i>Journal of Immunology</i> , 2002, 169, 366-374.	0.4	122
65	The Receptor Interaction Region of Tyk2 Contains a Motif Required for Its Nuclear Localization. <i>Journal of Biological Chemistry</i> , 2001, 276, 30812-30818.	1.6	31
66	Down-modulation of Type 1 Interferon Responses by Receptor Cross-competition for a Shared Jak Kinase. <i>Journal of Biological Chemistry</i> , 2001, 276, 47004-47012.	1.6	35
67	A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-alpha signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 8991-8996.	3.3	82
68	Downregulation of Interleukin-12 (IL-12) Responsiveness in Human T Cells by Transforming Growth Factor- $\beta$ : Relationship With IL-12 Signaling. <i>Blood</i> , 1999, 93, 1448-1455.	0.6	56
69	Induction of $\beta$ -2-Microglobulin ( $\beta$ 2-M) by Interferon- $\beta$ Requires Catalytically Active TYK2. <i>Journal of Biological Chemistry</i> , 1999, 274, 1891-1897.	1.6	29
70	The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon- $\beta$ . <i>Oncogene</i> , 1999, 18, 5727-5737.	2.6	255
71	The Janus kinase family of protein tyrosine kinases and their role in signaling. <i>Cellular and Molecular Life Sciences</i> , 1999, 55, 1523-1534.	2.4	111
72	Downregulation of Interleukin-12 (IL-12) Responsiveness in Human T Cells by Transforming Growth Factor- $\beta$ : Relationship With IL-12 Signaling. <i>Blood</i> , 1999, 93, 1448-1455.	0.6	7

#	ARTICLE	IF	CITATIONS
73	R�cepteurs aux cytokines et signalisation transmembranaire : le mod�le des interf�rons �/� <sup>2</sup> . Revue Francaise D'allergologie Et D'immunologie Clinique, 1998, 38, 886-888.	0.1	0
74	Interferon � Inhibits a Src-mediated Pathway Necessary for Shigella-induced Cytoskeletal Rearrangements in Epithelial Cells. Journal of Cell Biology, 1998, 143, 1003-1012.	2.3	52
75	Specific Contribution of Tyk2 JH Regions to the Binding and the Expression of the Interferon �/� <sup>2</sup> Receptor Component IFNAR1. Journal of Biological Chemistry, 1998, 273, 24723-24729.	1.6	87
76	Differences in Activity between � and � <sup>2</sup> Type I Interferons Explored by Mutational Analysis. Journal of Biological Chemistry, 1998, 273, 8003-8008.	1.6	64
77	Janus Kinase-dependent Activation of Insulin Receptor Substrate 1 in Response to Interleukin-4, Oncostatin M, and the Interferons. Journal of Biological Chemistry, 1997, 272, 24183-24190.	1.6	110
78	The amino-terminal region of Tyk2 sustains the level of interferon � receptor 1, a component of the interferon �/� receptor. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 11839-11844.	3.3	113
79	Identification of Signalling Components in Tyrosine Kinase Cascades Using Phosphopeptide Affinity Chromatography. Biochemical and Biophysical Research Communications, 1997, 234, 748-753.	1.0	5
80	The Structure, Regulation and Function of the Janus Kinases (JAKs) and the Signal Transducers and Activators of Transcription (STATs). FEBS Journal, 1997, 248, 615-633.	0.2	244
81	Post-translational up-regulation of the cell surface-associated � component of the human type I interferon receptor during differentiation of peripheral blood monocytes: role in the biological response to type I interferon. European Journal of Immunology, 1997, 27, 1075-1081.	1.6	17
82	IL4 and IL13 receptors share the � <sup>3</sup> c chain and activate STAT6, STAT3 and STAT5 proteins in normal human B cells. FEBS Letters, 1996, 393, 53-56.	1.3	94
83	Interferon-�-dependent Activation of Tyk2 Requires Phosphorylation of Positive Regulatory Tyrosines by Another Kinase. Journal of Biological Chemistry, 1996, 271, 20494-20500.	1.6	162
84	Distinct Domains of the Protein Tyrosine Kinase tyk2 Required for Binding of Interferon-�/� <sup>2</sup> and for Signal Transduction. Journal of Biological Chemistry, 1995, 270, 3327-3334.	1.6	140
85	Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science, 1994, 263, 92-95.	6.0	967
86	Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science, 1994, 263, 89-92.	6.0	787
87	Activation of the protein tyrosine kinase tyk2 by interferon alpha/beta. FEBS Journal, 1994, 223, 427-435.	0.2	59
88	The protein tyrosine kinase JAK1 complements defects in interferon-�/� <sup>2</sup> and � <sup>3</sup> signal transduction. Nature, 1993, 366, 129-135.	13.7	785
89	Early events in signalling by interferons. Trends in Biochemical Sciences, 1993, 18, 338-342.	3.7	189
90	A protein tyrosine kinase in the interferon �/� <sup>2</sup> signaling pathway. Cell, 1992, 70, 313-322.	13.5	903

#	ARTICLE	IF	CITATIONS
91	Rat fibroblasts expressing high levels of human c-myc transcripts are anchorage-independent and tumorigenic. <i>Journal of Cellular Physiology</i> , 1986, 126, 107-114.	2.0	12
92	Carcinogen induced asynchronous replication of polyoma DNA is mediated by a trans-acting factor. <i>Carcinogenesis</i> , 1986, 7, 1011-1017.	1.3	35
93	Amplification and excision of integrated polyoma DNA sequences require a functional origin of replication. <i>Cell</i> , 1984, 36, 943-949.	13.5	59